Skip to main content
  • Where to buy
  • Company
    • About us
    • Careers
    • Events
  • Support
    • Laboratory Planning
    • Register a Product
    • Register Your Product (USA & Canada Only)
  • Contact
  • U.S.A.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 日本
  • 中国
Home ELGA LabWater
  • Products
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • ELGA Full Product Range
  • Applications
    • Atomic Absorption Spectroscopy
    • Cell and Tissue Culture
    • Clinical Biochemistry
    • Electrochemistry
    • Gas Chromatography
    • General lab water requirement
    • Immunochemistry
    • Liquid Chromatography
    • Mass Spectrometry
    • Microbiology
    • Molecular Biology
    • Spectrophotometry
  • Technologies
    • Activated Carbon
    • Electrodeionization (EDI)
    • Filtration
    • Ion Exchange
    • PureSure
    • Reverse Osmosis
    • Ultraviolet
  • Impurities In Water
    • Dissolved Gases
    • Inorganic Compounds
    • Microorganisms & Bacteria
    • Organic Compounds
    • Particulates
  • Knowledge
    • Blog
    • Case Studies
    • Ultrapure water
    • Guides and White Papers
  • Products
    • PURELAB
    • CENTRA
    • MEDICA
      • Hubgrade
      • MEDICA BIOX
    • BIOPURE
    • ELGA Full Product Range
      • PURELAB® Classic
  • Applications
    • Atomic Absorption Spectroscopy
    • Cell and Tissue Culture
    • Clinical Biochemistry
    • Electrochemistry
    • Gas Chromatography
    • General lab water requirement
    • Immunochemistry
    • Liquid Chromatography
      • Hochleistungsflüssigkeitschromatographie (HPLC)
    • Mass Spectrometry
    • Microbiology
    • Molecular Biology
    • Spectrophotometry
  • Technologies
    • Activated Carbon
    • Electrodeionization (EDI)
    • Filtration
    • Ion Exchange
    • PureSure
    • Reverse Osmosis
    • Ultraviolet
  • Impurities In Water
    • Dissolved Gases
    • Inorganic Compounds
    • Microorganisms & Bacteria
    • Organic Compounds
    • Particulates
  • Knowledge
    • Blog
      • Analytical Chemistry
      • Clinical & Pharma
      • Cool Science
      • Environment and sustainability
      • Life in the lab
      • Purelab product design
      • Science of the future
      • Water Purity
      • Water in the lab
    • Case Studies
      • Abbott Diagnostics chooses ELGA MEDICA systems in South Asia
      • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
      • Argenta chooses DKSH New Zealand to deliver Ultrapure water in Animal Pharma
      • Clean Water for a Clean Future
      • LS Scientific & ELGA deliver UltraPure water to the NAFDAC Laboratory
      • Lifebrain Group chooses ELGA as water partner for new modern 24/7 PCR-COVID-19 laboratory in Vienna, Austria.
      • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
      • DASA: The biggest medical diagnostics company in Brazil
      • ELGA helps immuneserology labs maximize uptime
      • Fondazione Telethon Continues to Choose ELGA Labwater as a Trusted Partner
      • Importance of ultrapure Type 1+ water for the development of generic medicines
      • MEDICA® Pro selected for Siemens ADVIA® analyzers at City General Hospital
      • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
      • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
      • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
      • PURELAB® flex: an ideal training system for today's research method
      • Powering Cutting-Edge Gene Research
      • Sichere Reinstwasserversorgung für präzise Produkttests
      • Zentrale Reinstwasser-Aufbereitung für Analyser
      • ELGA LabWater and Beckman Coulter Join Forces
      • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
      • Unlocking the secrets of the Antarctic with the aid of ultrapure water
      • Advancing Genetic Technologies
      • Cross Infection Control: Pure and Simple
      • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
    • Ultrapure water
    • Guides and White Papers
      • HPLC Water Purity
      • HPLC in Pharma
      • Reducing Clinical Risks
      • Sustainability
  • U.S.A.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 日本
  • 中国
  • Privacy policy
  • Terms & Conditions
  • Global Legal Compliance
  • Patents
  • Impressum

Let's talk about lab water

  • Categories
    • Analytical Chemistry
    • Biotechnology
    • Clinical & Pharma
    • Cool Science
    • Environment & Sustainability
    • Future Science
    • Life in The Lab
    • Life Science Results
    • PURELAB Product Design
    • Science of the Future
    • Water In The Lab
    • Water Purity
  • Authors
    • ELGA Editorial Team_cloned
    • ELGA Editorial Team
    • Natasha Zarach
    • Dr Paul Whitehead
    • Dr Alison Halliday
    • John Walker
Analytical Chemistry
Water Purity

Could Faecal Testing Help Personalise Cancer Treatment?

22 Jun 2020
- by Dr Alison Halliday

Scientific Testing

A new study suggests that measuring short-chain fatty acids in the gut may offer a way to predict which cancer patients will benefit from immunotherapy.


Cancer therapies that target elements of the immune system – immunotherapies – are showing remarkable results for many patients. So-called ‘immune checkpoint inhibitors’ work by interfering with the mechanism that cancer cells use to evade destruction by the body’s immune system. Examples include nivolumab and pembrolizumab, which target a molecule on the surface of cells called PD–1.

Treating patients with immune checkpoint inhibitors can shrink tumours and improve survival rates, even for whom other therapies have failed. However, the response to these drugs varies widely from person to person – particularly for those with solid tumours.

If clinicians could predict who will benefit from cancer immunotherapies in advance, this would help spare many patients from the risk of unnecessary side effects. Defining the factors that can influence this variability in response will also improve our understanding of how these treatments work, identifying new opportunities for widening their effectiveness in the future.

The Gut Microbiome is a Suspect

Several studies have suggested that the population of microorganisms in our gut may influence the success of cancer immunotherapies. But the mechanisms behind this potential association remain unclear. One suspect are the short-chain fatty acids, which are the major end–products of gut microbiome–mediated metabolism. These molecules are thought to have wide-ranging effects on the whole body – including in modulating the immune response. 

In a new study, published in JAMA Network Open, scientists set out to explore whether short-chain fatty acids are associated with the clinical outcomes of patients with solid tumours treated with nivolumab or pembrolizumab.1

Evaluating Short-Chain Fatty Acid Concentrations

The researchers recruited 52 patients with solid tumours before they started treatment with nivolumab or pembrolizumab. They collected faecal and plasma samples and measured the concentrations of various short-chain fatty acids using ultra–high–performance liquid chromatography coupled with tandem mass spectrometry.

For these experiments, they used ultrapure water from an ELGA PURELAB® flex 5 water purification system, minimising the risk of introducing contaminants that may affect their results.

The scientists carried out scans to measure the size of the patients’ tumours at regular intervals over the study. They then carried out statistical analyses to evaluate if the levels of short-chain fatty acids were related to their response to treatment. They found that high concentrations of acetic acid, propionic acid, butyric acid and valeric acid in faecal samples – and isovaleric acid in plasma – were associated with patients living longer without their disease getting any worse. 

A Non–Invasive Test

This is the first study to identify a link between short-chain fatty acids and the effectiveness of PD–1 treatment for solid cancers. 

If these results are confirmed in larger studies, testing faecal samples from patients with solid tumours could offer a relatively simple way to predict who may benefit from nivolumab or pembrolizumab– paving the way to a more personalised approach to cancer immunotherapy in the future.

Why Choose ELGA LabWater?

ELGA’s expert engineers, chemists and scientists are at the forefront of technological innovation. We continue to introduce game-changing features to the laboratory water market.
 

Reference:

  1. Nomura M, et al. Association of Short–Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment with Nivolumab or Pembrolizumab in Patients with Solid Cancer Tumors. JAMA Network Open 2020;3(4):e202895


Dr Alison Halliday

After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

risk whitepaper

When lives are at stake, there is no margin for error. Your clinical analyser must receive a constant and reliable supply of CLRW. 

Find out how to protect your test results

                   Click Here

 

Highlights

16 Jan 2023
Measuring the effects of indoor air pollution
10 Jan 2023
A novel approach to wound healing
12 Dec 2022
3D bioprinting probiotics capsules
4 Nov 2022
Wie mikrobielle Brennstoffzellen zur Lösung von zwei dringenden globalen Umweltproblemen beitragen könnten
24 Oct 2022
New ‘designer drug’ identified in e-cigarettes
6 Oct 2022
Curcumin-beladene Nanopartikel ermöglichen neue Behandlung von Lungenkrebs
3 Oct 2022
Controlling pathogens using natural grapevines extracts
22 Sep 2022
Measuring indigestible sugars in breast milk

Categories

  • Analytical Chemistry
  • Biotechnology
  • Clinical & Pharma
  • Cool Science
  • Environment & Sustainability
  • Future Science
  • Life in The Lab
  • Life Science Results
  • PURELAB Product Design
  • Science of the Future
  • Water In The Lab
  • Water Purity

Video

  • Enquiry
  • Get a Quote
  • Book a Demo
  • Find an Approved Partner

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Get a Quote

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Book a Demo

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

ELGA LabWater North America
5 Earl Ct Suite 100
Woodridge, IL 60517
USA

Tel: 630-343-5251

ELGA LabWater UK Headquarters

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
T: +44 (0) 203 567 7300
F: +44 (0) 203 567 7205

Case Studies

  • Abbott Diagnostics
  • DASA Medical Diagnostics
  • NeoDIN Medical Institute
  • North Staffordshire NHS Trust
  • Olsberg Vocational College

Resources

  • Learn About Ultrapure Water
  • Guides and White Papers
  • Purification Technologies
  • Applications
  • Impurities In Water

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • Language
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Other Veolia Sites
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies

© VWS (UK) Ltd. trading as ELGA LabWater. 2023 - All rights reserved.
ELGA is the global laboratory water brand name of Veolia.

  • Privacy policy
  • Terms & Conditions
  • Global Legal Compliance
  • Patents
  • Impressum
Elga Veolia
TOP

© 2017 ELGA Veolia